This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Role of immunotherapy in localized muscle invasive urothelial cancer
Ther Adv Med Oncol. 2021 ;13 :17588359211045858
PMID: 34567274 PMCID: PMC8461126 URL: https://www.ncbi.nlm.nih.gov/pubmed/34567274
AbstractThe standard treatment for non-metastatic muscle-invasive bladder cancer (MIBC) is cisplatin-based neoadjuvant chemotherapy followed by radical cystectomy or trimodality therapy with chemoradiation in select patients. Pathologic complete response (pCR) to neoadjuvant chemotherapy is a reliable predictor of overall and disease-specific survival in MIBC. A pCR rate of 35-40% is attained with neoadjuvant cisplatin-based chemotherapy. With the approval of immune checkpoint inhibitors (ICIs) for the treatment of metastatic urothelial cancer, these agents are now being studied in the neoadjuvant setting for MIBC. We describe the results from clinical trials using single agent ICI, ICI/ICI and ICI/chemotherapy combination therapies in the neoadjuvant setting for MIBC. These single-arm clinical trials have demonstrated safety and pCR comparable to cisplatin-based chemotherapy. Neoadjuvant ICI is a promising approach for cisplatin-ineligible patients, and the role of adding ICIs to cisplatin-based chemotherapy is also being investigated in randomized phase III clinical trials. Ongoing biomarker research to suggest a response to neoadjuvant ICIs will also guide appropriate treatment selection. We also describe the studies using ICIs for adjuvant therapy and in combination with chemoradiation.
Notes1758-8359 Kaur, Jasmeet Orcid: 0000-0002-4507-8157 Choi, Woonyoung Geynisman, Daniel M Plimack, Elizabeth R Ghatalia, Pooja Journal Article Review Ther Adv Med Oncol. 2021 Sep 22;13:17588359211045858. doi: 10.1177/17588359211045858. eCollection 2021.